Program
Granulocyte Colony-Stimulating Factor
Also written as “G-CSF plus plerixafor”, “G-CSF Plus Plerixafor” and “G-CSF”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Non-Hodgkin · Sarcoma · Infertility, Female · Hot Flashes, led by 6 companies.
Drug pageGranulocyte Colony-Stimulating Factor: every studyMany companies study it; this page follows only the 16 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 110 open or running | phase 4since Oct 9, 2021 | Feb 11, 2005 | none ahead |
| Axaron Bioscienceits history only | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| CSLits history only | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| MenoGeniXits history only | 10 open or running | phase 1since Jul 30, 2018 | Jul 30, 2018 | none ahead |
| Newlife Fertility Centre | 11 open or running | phase 4since Dec 8, 2023 | Dec 8, 2023 | none ahead |
| Terumoits history only | 10 open or running | no phasesince Sep 23, 2014 | Sep 23, 2014 | none ahead |
Also a collaborator on its studies: AnorMED.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Newlife Fertility Centre only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 8, 2023First study: phase 4 study in InfertilityFirst studyNCT06174298 · 300 planned · Canada
- Feb 29, 2024Named granulocyte colony-stimulating factorINNProposed as its International Nonproprietary Name in WHO's List 130
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Newlife Fertility Centre leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06174298Infertility · Canada | 4 | Recruiting | Jan 10, 2025 | 300 |
How it is read
Names in the registry
- “G-CSF plus plerixafor”, 4 entries
- “G-CSF Plus Plerixafor”, 4 entries
- “G-CSF”, 3 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Granulocyte colony-stimulating factor plus plerixafor”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Sarcoma, 1 study
- Infertility, Female, 1 study
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.